In the latest CEO Corner segment, Thomas K. Equels, CEO of B2i Digital Featured Company AIM ImmunoTech (NYSE American: $AIM) https://lnkd.in/erRzxGa9, addresses investor questions and gives updates on the company’s financials and clinical progress, especially the DURIPANC study, a cornerstone of AIM’s oncology program.
Regarding AIM’s financial position, Equels states: “As of March 31st, 2024, we reported cash, cash equivalents, and marketable securities of $10.9 million.” He adds, “Aside from cash, we can also more recently report stockholder equity of $6.9 million.”
Concerning the DURIPANC study with AstraZeneca, conducted at Erasmus Medical Center in the Netherlands, which Equels describes as “one of the finest cancer research centers in Europe,” he shares: “The combination of Ampligen and Imfinzi was found to be generally well tolerated with no severe adverse events or dose-limiting toxicities.” He further notes, “I am pleased to say that enrollment and dosing of the second cohort of patients in the DURIPANC study has commenced.”
Equels emphasizes the study’s progress: “We will keep you advised as progress occurs with this important study. It’s a fairly fast-moving study, I’m pleased to say.”
See the entire CEO Corner video here: https://lnkd.in/eNDB6XK2
AIM is committed to transparent communication and ongoing clinical advancements for Ampligen, its flagship product. We commend the AIM management team, including CEO Tom Equels, COO Peter Rodino III, CMO David Strayer, Chris McAleer PhD, and CFO Robert Dickey, for their dedication to advancing a new therapy for advanced metastatic pancreatic cancer patients.
For any questions, please contact AIM’s investor relations firm, JTC IR, led by Jenene Thomas. Stay tuned for more updates from AIM’s CEO Corner series.
#ImmunoOncology#PancreaticCancer#ClinicalTrials#Biotech#Ampligen#AIMImmunoTech#B2iDigital
Hello and thank you very much for joining me for another CEO Corner segment. My name is Tom Equals and I am CEO of AIM Immunotech. I very much appreciate your time and attention. We're getting a lot of positive feedback on our CEO Corner segments and also some great ideas from those viewers that we have for new topics, some of which likely would not fill a whole segment. For this segment, for example, I'd like to address just a couple of questions that have recently been submitted for consideration. So I will get started. A frequently asked question is can we discuss the company's financials regarding our cash position as a publicly listed company, I'm limited to discussing what we reported in our last quarterly filing or any subsequent financial related filings. From that cash perspective, as of March 31, 2024, we reported cash, cash equivalents and marketable securities of $10.9 million. Aside from cash, we can also more recently report stockholder equity of $6.9 million. The next question which we have been recently asked is the status of our collaboration with AstraZeneca in a Phase 1B2 study of Ampligen and AstraZeneca drug Imfinzi as a combination therapy for late stage pancreatic cancer, which we refer to as Durupan Q. We recently reported that the investigators at Erasmus Medical Center in the Netherlands, this is one of the finest Cancer Research centers in Europe, have completed the safety evaluation of patients enrolled in the first dose level of the dose escalation design. In the Phase 1B2 study, the combination of Ampligen and emphysema was found to be generally well tolerated with no severe adverse events or dose limiting toxicities. As an update, I am pleased to say that enrollment and dosing of the 2nd cohort of patients in the Durupan study has commenced. We will keep you advised as progress occurs with this important study and it's a fairly fast moving study, I'm pleased to say. With that, I thank you for tuning in for another segment of CEO Corner. Please feel free to submit any topics or questions you may have at the bottom of our CEO Corner page. I look forward to connecting with you all very soon. And wish you all the best, Thank you.
Global Citizen VR Educators| PCA, Special Education, ASD Advocate
1wFantastic update!